Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biote (BTMD) Net Cash Flow (2021 - 2025)

Biote has reported Net Cash Flow over the past 5 years, most recently at -$3.9 million for Q4 2025.

  • Quarterly results put Net Cash Flow at -$3.9 million for Q4 2025, down 449.6% from a year ago — trailing twelve months through Dec 2025 was -$15.2 million (up 69.33% YoY), and the annual figure for FY2025 was -$15.2 million, up 69.33%.
  • Net Cash Flow for Q4 2025 was -$3.9 million at Biote, down from $8.4 million in the prior quarter.
  • Over the last five years, Net Cash Flow for BTMD hit a ceiling of $55.0 million in Q2 2022 and a floor of -$52.4 million in Q2 2024.
  • Median Net Cash Flow over the past 5 years was $1.0 million (2022), compared with a mean of $348100.0.
  • Biggest five-year swings in Net Cash Flow: plummeted 1812.05% in 2022 and later surged 1228.06% in 2023.
  • Biote's Net Cash Flow stood at $3.8 million in 2021, then plummeted by 54.1% to $1.8 million in 2022, then surged by 1228.06% to $23.4 million in 2023, then tumbled by 95.21% to $1.1 million in 2024, then tumbled by 449.6% to -$3.9 million in 2025.
  • The last three reported values for Net Cash Flow were -$3.9 million (Q4 2025), $8.4 million (Q3 2025), and -$22.1 million (Q2 2025) per Business Quant data.